title: Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
authors.forename: Li
authors.initials: L
authors.lastname: Ding
authors.forename: Heng-Xiang
authors.initials: HX
authors.lastname: Wang
authors.forename: Mei
authors.initials: M
authors.lastname: Xue
authors.forename: Ling
authors.initials: L
authors.lastname: Zhu
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Hong-Min
authors.initials: HM
authors.lastname: Yan
authors.forename: Lian-Ning
authors.initials: LN
authors.lastname: Duan
authors.forename: Zhi-Dong
authors.initials: ZD
authors.lastname: Wang
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D003841:Deoxycytidine; D014747:Vinblastine; D000069286:Bortezomib; D000077235:Vinorelbine; D007069:Ifosfamide; D011241:Prednisone; D000093542:Gemcitabine